The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1230
March 13, 2006
View Complete Issue         Table of Contents 2019 
A Levalbuterol Metered-Dose Inhaler (Xopenex HFA) for Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Levalbuterol Metered-Dose Inhaler (Xopenex HFA) for Asthma
March 13, 2006 (Issue: 1230)
Levalbuterol, the R-isomer of the beta-2 adrenergic agonist albuterol, is now available in the US as a metered-dose inhaler (Xopenex HFA - Sepracor) for treatment of asthma in patients ≥ 4 years old. Levalbuterol has been available since 1999...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Levalbuterol Metered-Dose Inhaler (Xopenex HFA) for Asthma
Article code: 1230a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.